An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease

Kidney International

Volumn 60, Issue 3, 2001, Pages 1106-1113

  Wrone, Elizabeth M ^a,b   Zehnder, James L ^a,b   Hornberger, John M ^a,b   McCann, Linda M ^a,b   Coplon, Norman S ^a,b   Fortmann, Stephen P ^a,b  

^a Satellite Research   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; C677T genotype; Dialysis; End stage renal disease; Folate depletion; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase; Vascular pathophysiology

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; CREATININE; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DIALYSIS; DISEASE MARKER; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; GENOTYPE; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0035720334     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0600031106.x     Document Type: Article

References (39)

1. Homocysteine and its disulfide derivatives: A suggested consensus terminology
2. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
3. MTHFR association with arteriosclerotic vascular disease?
4. The common "thermolabile" variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia
5. Common mutation in methylenetetrahydrofolate reductase: Correlation with homocysteine and other risk factors for vascular disease
6. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
7. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients
8. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
9. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening: The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
10. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
11. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients
12. Folic acid, pyridoxine, cobalamin, and homocysteine and their relationship to cardiovascular disease in end-stage renal disease
13. No net renal extraction of homocysteine in fasting humans
14. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
15. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass
16. Malnutrition, cardiac disease, and mortality: An integrated point of view
17. Optimal blood pressure: How low should we go?
18. Overweight, obesity, and health risk
19. "U" curve association of blood pressure and mortality in hemodialysis patients: Medical Directors of Dialysis Clinic, Inc.
20. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients
21. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities
22. Epidemiology of cardiovascular risk factors in chronic renal disease
23. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study
24. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study
25. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery
26. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
27. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
28. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients
29. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
30. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
31. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
32. A common methylenetetrahydrofolate reductase gene mutation and longevity
33. Hyperhomocysteinemia in high-aged subjects: Relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation
34. The USRDS and its products: United States Renal Data System
35. Survival advantage in Asian American end-stage renal disease patients
36. Diabetic nephropathy and end-stage renal disease in Mexican Americans
37. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart study